{"title":"针对三叉神经节的α6GABAA受体阳性变构调节剂预防和终止两性慢性眶周异常性疼痛和头性疼痛的机制和临床前比较研究","authors":"Xin-Chen Chang , Chen-Jiun Yeh , Yi-Ting Pan , Yueh-Peng Chen , Dishary Sharmin , James Cook , Yu-Cheng Pei , Lih-Chu Chiou","doi":"10.1016/j.biopha.2025.118344","DOIUrl":null,"url":null,"abstract":"<div><div>Migraine remains an unmet medical need, even with new calcitonin gene-related peptide (CGRP)-targeting treatments. The α6 subunit (Gabra6)-containing GABA<sub>A</sub> receptors (α6GABA<sub>A</sub>Rs) are abundant in trigeminal ganglia (TG). We evaluated the possible anti-migraine efficacy and mechanism of DK-I-56–1, a druggable α6GABA<sub>A</sub>R-selective positive allosteric modulator (PAM), using a chronic migraine model induced by repeated intermittent nitroglycerin (riNTG) injections (10 mg/kg, <em>i.p.</em>, every 2 days for a total of 5 doses). Chronic and acute allodynic responses of riNTG-treated ICR mice of both sexes were assessed by reduced mechanical withdrawal thresholds in their periorbital areas, and their chronic cephalic pain by elevated grimace scores. riNTG induced long-lasting chronic periorbital allodynia and cephalic pain, and one NTG injection caused acute allodynia. Daily DK-I-56–1 prevented chronic allodynia and cephalic pain, and abolished acute allodynia in both sexes. Anti-allodynic and cephalic pain-relieving effects of DK-I-56–1 (10 mg/kg, <em>i.p.</em>) were mimicked by topiramate (30 mg/kg, <em>i.p.</em>), antagonized by <em>i.p.</em> furosemide, an α6GABA<sub>A</sub>R antagonist, and nullified in <em>Gabra6</em>-knockout ICR mice. However, olcegepant (1 mg/kg, <em>i.p.</em>) only partially prevented cephalic pain. In dissociated TG neurons, DK-I-56–1 induced a furosemide-sensitive potentiation of GABA-induced current and depolarization. However, DK-I-56–1 did not altered increased inflammatory cytokines, down-regulated glutamate decarboxylase 65 kDa (GAD65), and Gabra6 protein levels in TG of riNTG-treated mice. Therefore, DK-I-56–1 may have the potential to prevent and abort migraines by potentiating GABA-induced depolarization in TG neurons via α6GABA<sub>A</sub>Rs, offering efficacy comparable to that of topiramate but superior to olcegepant as a novel migraine therapy.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"189 ","pages":"Article 118344"},"PeriodicalIF":7.5000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"α6GABAA receptor positive allosteric modulators targeting trigeminal ganglia for preventing and aborting chronic periorbital allodynia and cephalic pain in both sexes: A mechanistic and comparative preclinical study\",\"authors\":\"Xin-Chen Chang , Chen-Jiun Yeh , Yi-Ting Pan , Yueh-Peng Chen , Dishary Sharmin , James Cook , Yu-Cheng Pei , Lih-Chu Chiou\",\"doi\":\"10.1016/j.biopha.2025.118344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Migraine remains an unmet medical need, even with new calcitonin gene-related peptide (CGRP)-targeting treatments. The α6 subunit (Gabra6)-containing GABA<sub>A</sub> receptors (α6GABA<sub>A</sub>Rs) are abundant in trigeminal ganglia (TG). We evaluated the possible anti-migraine efficacy and mechanism of DK-I-56–1, a druggable α6GABA<sub>A</sub>R-selective positive allosteric modulator (PAM), using a chronic migraine model induced by repeated intermittent nitroglycerin (riNTG) injections (10 mg/kg, <em>i.p.</em>, every 2 days for a total of 5 doses). Chronic and acute allodynic responses of riNTG-treated ICR mice of both sexes were assessed by reduced mechanical withdrawal thresholds in their periorbital areas, and their chronic cephalic pain by elevated grimace scores. riNTG induced long-lasting chronic periorbital allodynia and cephalic pain, and one NTG injection caused acute allodynia. Daily DK-I-56–1 prevented chronic allodynia and cephalic pain, and abolished acute allodynia in both sexes. Anti-allodynic and cephalic pain-relieving effects of DK-I-56–1 (10 mg/kg, <em>i.p.</em>) were mimicked by topiramate (30 mg/kg, <em>i.p.</em>), antagonized by <em>i.p.</em> furosemide, an α6GABA<sub>A</sub>R antagonist, and nullified in <em>Gabra6</em>-knockout ICR mice. However, olcegepant (1 mg/kg, <em>i.p.</em>) only partially prevented cephalic pain. In dissociated TG neurons, DK-I-56–1 induced a furosemide-sensitive potentiation of GABA-induced current and depolarization. However, DK-I-56–1 did not altered increased inflammatory cytokines, down-regulated glutamate decarboxylase 65 kDa (GAD65), and Gabra6 protein levels in TG of riNTG-treated mice. Therefore, DK-I-56–1 may have the potential to prevent and abort migraines by potentiating GABA-induced depolarization in TG neurons via α6GABA<sub>A</sub>Rs, offering efficacy comparable to that of topiramate but superior to olcegepant as a novel migraine therapy.</div></div>\",\"PeriodicalId\":8966,\"journal\":{\"name\":\"Biomedicine & Pharmacotherapy\",\"volume\":\"189 \",\"pages\":\"Article 118344\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicine & Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0753332225005384\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0753332225005384","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
α6GABAA receptor positive allosteric modulators targeting trigeminal ganglia for preventing and aborting chronic periorbital allodynia and cephalic pain in both sexes: A mechanistic and comparative preclinical study
Migraine remains an unmet medical need, even with new calcitonin gene-related peptide (CGRP)-targeting treatments. The α6 subunit (Gabra6)-containing GABAA receptors (α6GABAARs) are abundant in trigeminal ganglia (TG). We evaluated the possible anti-migraine efficacy and mechanism of DK-I-56–1, a druggable α6GABAAR-selective positive allosteric modulator (PAM), using a chronic migraine model induced by repeated intermittent nitroglycerin (riNTG) injections (10 mg/kg, i.p., every 2 days for a total of 5 doses). Chronic and acute allodynic responses of riNTG-treated ICR mice of both sexes were assessed by reduced mechanical withdrawal thresholds in their periorbital areas, and their chronic cephalic pain by elevated grimace scores. riNTG induced long-lasting chronic periorbital allodynia and cephalic pain, and one NTG injection caused acute allodynia. Daily DK-I-56–1 prevented chronic allodynia and cephalic pain, and abolished acute allodynia in both sexes. Anti-allodynic and cephalic pain-relieving effects of DK-I-56–1 (10 mg/kg, i.p.) were mimicked by topiramate (30 mg/kg, i.p.), antagonized by i.p. furosemide, an α6GABAAR antagonist, and nullified in Gabra6-knockout ICR mice. However, olcegepant (1 mg/kg, i.p.) only partially prevented cephalic pain. In dissociated TG neurons, DK-I-56–1 induced a furosemide-sensitive potentiation of GABA-induced current and depolarization. However, DK-I-56–1 did not altered increased inflammatory cytokines, down-regulated glutamate decarboxylase 65 kDa (GAD65), and Gabra6 protein levels in TG of riNTG-treated mice. Therefore, DK-I-56–1 may have the potential to prevent and abort migraines by potentiating GABA-induced depolarization in TG neurons via α6GABAARs, offering efficacy comparable to that of topiramate but superior to olcegepant as a novel migraine therapy.
期刊介绍:
Biomedicine & Pharmacotherapy stands as a multidisciplinary journal, presenting a spectrum of original research reports, reviews, and communications in the realms of clinical and basic medicine, as well as pharmacology. The journal spans various fields, including Cancer, Nutriceutics, Neurodegenerative, Cardiac, and Infectious Diseases.